Show simple item record

dc.contributor.authorMansi, Kamel
dc.contributor.authorHaynes, Euan
dc.contributor.authorAdams, Clive E.
dc.date.accessioned2017-10-30T13:32:48Z
dc.date.available2017-10-30T13:32:48Z
dc.date.issued2012
dc.identifier.citationKoch, K., Mansi, K., Haynes, E. & Adams, C. E. (2012). Trifluoperazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, (11).en
dc.identifier.other10.1002/14651858.CD010226
dc.identifier.urihttp://hdl.handle.net/20.500.12904/9782
dc.description.abstractThis is the prodrug tocol for a review and there is no abstract. The objectives are as follows: To determine the absolute effects of trifluoperazine for schizophrenia and schizophrenia-like illnesses when compared with placebo.en
dc.formatFull text uploaded
dc.subjectDrug therapyen
dc.subjectSchizophreniaen
dc.titleTrifluoperazine versus placebo for schizophreniaen
dc.typeArticle
refterms.dateFOA2021-06-14T11:07:42Z


Files in this item

Thumbnail
Name:
Koch 2012 1-11.pdf
Size:
179.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record